Evidence map›Paper›PMID 37409961›Full record

ArticleMicrobiology spectrum2023

Acinetobacter baumannii GC2 Sublineage Carrying the

Christopher J Harmer, Steven J Nigro, Ruth M Hall

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. TnCurrent research in microbial sciences · 2026
    Article
  3. Article
  4. Article
  5. Genomic characterization of multidrug-resistant clinicalFrontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. ISMicrobiology and molecular biology reviews : MMBR · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Christopher J HarmerSchool of Life and Environmental Sciences, The University of Sydney, New South Wales, Australia.ORCID 0000-0003-1486-454X
Steven J NigroSchool of Life and Environmental Sciences, The University of Sydney, New South Wales, Australia.
Ruth M HallSchool of Life and Environmental Sciences, The University of Sydney, New South Wales, Australia.ORCID 0000-0003-2062-3312
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aminoglycoside antibiotics amikacin, gentamicin, and tobramycin are important therapeutic options for Acinetobacter iinfections. Several genes that confer resistance to one or more of these antibiotics are prevalent in the globally distributed resistant clones of Acinetobacter baumannii, but the

Indexed as

Acinetobacter baumanniiAmikacinAminoglycosidesAnti-Bacterial AgentsAustraliaClone CellsDrug Resistance, BacterialGentamicinsInterleukin-1 Receptor-Like 1 ProteinMicrobial Sensitivity TestsNetilmicinTobramycinAmikacinAminoglycosidesAnti-Bacterial AgentsGentamicinsInterleukin-1 Receptor-Like 1 ProteinNetilmicinTobramycinaac(6′)-ImAcinetobacter baumannii evolutionaminoglycoside resistanceantibiotic resistancecapsule locusgenomic islandglobal clone 1insertion sequenceinsertion sequence ISAba1

Identifiers

PMID37409961
PMCPMC10434200
OpenAlexW4383301941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.